Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Recurrence 28Leukemia 24Vomiting 23Neoplasms, Plasma Cell 20Lymphoma 18Neoplasms 16Nausea 13Burkitt Lymphoma 11Prostatic Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Follicular 5Lung Neoplasms 5Hodgkin Disease 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Paraproteinemias 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Rituximab 2Epoetin Alfa 2Early Intervention, Educational 2Dexamethasone 2Darbepoetin alfa 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Vincristine 1Sucrose 1Prednisone 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Doxorubicin 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoproliferative Disorders × Dexamethasone × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡